A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
A phase 2 trial of Belzutifan, Cabozantinib in renal cell carcinoma, run by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), active and no longer recruiting.
Overview
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) is a phase 2 interventional study registered as NCT03634540 by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), with 118 participants planned, started 2018-09-27 and due to reach its primary completion in 2027-02-26. Interventions recorded: Belzutifan, Cabozantinib. Conditions listed: Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Belzutifan, Cabozantinib, Renal cell carcinoma.
- TrialLITESPARK-012
Shares Belzutifan, Renal cell carcinoma.
- TargetAXL
Shares Cabozantinib, Renal cell carcinoma.
- TrialA Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6
Shares Belzutifan, Renal cell carcinoma.
- TrialStudy of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Shares Cabozantinib, Renal cell carcinoma.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Belzutifan, Cabozantinib.
- TrialSubstudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (
Shares Belzutifan, Renal cell carcinoma.